Generalized Pustular Figurate Erythema in Patients with COVID-19 Treated with Hydroxychloroquine: A Systematic Review

A severe distinctive cutaneous drug reaction, generalized pustular figu- rate erythema, closely linked with hydroxychloroquine (HCQ), has been documented. It is distinguishable from AGEP by its longer incubation, more varied morphology (initially urticarial and later targetoid, arcuate plaques), recalcitrance to therapy and longer disease course. Aim of the article is to review the recognized entity associated with ingestion of hy- droxychloroquine in patients infected with COVID-19. A systematic review using electronic search was performed. Inclusion criteria: n pa- tients with COVID-19 demonstrated by PCR, with typical clinical features of AGEP/ GPFE or atypical features associated with typical histopathology. We used the (JBI) Critical Appraisal Checklist for Case Reports for the qualitive assessment. We included 13 publications. Their overall quality was good to moderate. Only 27.3% of the patients had a severe COVID-19 course. The mean lag time between trigger exposure and rash development was 24 days. Only 15.38% of the reported AGEP were clinically typical, while the remaining 69.23 % were suggestive of GPFE. Unfortunate- ly, 2 patients died secondary to massive pulmonary embolism. In COVID-19 infection, we suggest reconsidering treating established COVID-19 em- pirically with HCQ, as both triggers can augment the subsequent cytokine storm, in- ducing a severe drug reaction and possibly increasing the risk of thrombo-embolic events

Generalized Pustular Figurate Erythema in Patients with COVID-19 Treated with Hydroxychloroquine: A Systematic Review

A severe distinctive cutaneous drug reaction, generalized pustular figu- rate erythema, closely linked with hydroxychloroquine (HCQ), has been documented. It is distinguishable from AGEP by its longer incubation, more varied morphology (initially urticarial and later targetoid, arcuate plaques), recalcitrance to therapy and longer disease course. Aim of the article is to review the recognized entity associated with ingestion of hy- droxychloroquine in patients infected with COVID-19. A systematic review using electronic search was performed. Inclusion criteria: n pa- tients with COVID-19 demonstrated by PCR, with typical clinical features of AGEP/ GPFE or atypical features associated with typical histopathology. We used the (JBI) Critical Appraisal Checklist for Case Reports for the qualitive assessment. We included 13 publications. Their overall quality was good to moderate. Only 27.3% of the patients had a severe COVID-19 course. The mean lag time between trigger exposure and rash development was 24 days. Only 15.38% of the reported AGEP were clinically typical, while the remaining 69.23 % were suggestive of GPFE. Unfortunate- ly, 2 patients died secondary to massive pulmonary embolism. In COVID-19 infection, we suggest reconsidering treating established COVID-19 em- pirically with HCQ, as both triggers can augment the subsequent cytokine storm, in- ducing a severe drug reaction and possibly increasing the risk of thrombo-embolic events